SCHEMBL1444743

SCHEMBL1444743

COc1cnc(-c2ccccn2)nc1C(N)CC(C)C

nearest known ligand 0.62

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 8/20 0.62
L3MBTL1 Q9Y468 11/20 0.56
SMN1; SMN2 Q16637 8/20 0.56
LMNA P02545 5/20 0.56
MAPT P10636 4/20 0.56
MITF O75030 1/20 0.56
HTT P42858 3/20 0.53
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 5/20 0.50
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
PPP1CA P62136 4/20 0.50
TDP1 Q9NUW8 2/20 0.50
POLB P06746 1/20 0.47
GAA P10253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1443054 0.88 TRPM8 (0.60) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL1443077 0.84 TRPM8 (0.58) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL1443370 0.84 TRPM8 (0.61) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL1443064 0.74 L3MBTL1 (0.65) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL11900357 0.74 TRPM8 (0.71) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL1444748 0.73 L3MBTL1 (0.70) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL10270667 0.73 TRPM8 (1.00) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL1444745 0.72 TRPM8 (0.72) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL1701097 0.72 TRPM8 (1.00) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT
SCHEMBL29968698 0.72 TRPM8 (1.00) TRPM8L3MBTL1SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473486-B2 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2021-09-22 EP disclosed
EP-2473486-B1 PYRIMIDINES AS HEPCIDINE ANTAGONISTS VIFOR INT AG (CH) 2015-10-28 EP disclosed
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists VIFOR (INTERNATIONAL) AG (CH) 2012-08-09 US disclosed
EP-2473486-A1 NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2012-07-11 EP disclosed
WO-2011026835-A1 NOVEL PYRIMIDINE AND TRIAZINE HEPCIDINE ANTAGONISTS VIFOR (INTERNATIONAL) AG (CH) 2011-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202806-A1 Novel Pyrimidine- And Triazine-Hepcidine Antagonists HAMP, DHPS, SLC40A1 TRPM8 2345/4885L3MBTL1 3829/4885SMN1; SMN2 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.